Fixed-income seeks clarity as 15c2-11 carve-out debated

SEC clarifies Rule 15c2-11 applies to equities, not fixed-income

The U.S. Securities and Exchange Commission has proposed clarifying that Rule 15c2-11 applies to equities and not to fixed-income securities, according to the U.S. Securities and Exchange Commission. The move seeks to resolve uncertainty that arose when market participants questioned whether the rule extended to bonds and asset-backed instruments after recent staff interpretations.

Industry legal analyses note the rule has historically been applied to equity markets, not debt. according to the Structured Finance Association, there is no record of the rule’s enforcement in fixed-income or structured products (structuredfinance.org/wp-content/uploads/2022/12/SFA-15c2-11-Brief-FINAL.pdf).

Why SEC Rule 15c2-11 scope matters now

A legislative fix has been introduced to align the rule’s scope with equity markets. as published on Congress.gov, H.R. 3959 (introduced June 12, 2025) would add a statutory exemption stating Rule 15c2-11 does not apply to quotations of fixed-income securities and defines fixed income broadly (congress.gov/bill/119th-congress/house-bill/3959/text).

Requests for continued relief underscore operational stakes. According to the Investment Company Institute, a November 22, 2024 joint letter argued market participants historically did not view the rule as applicable to fixed income and that its provisions are ill-suited for those markets (ici.org/system/files/2024-11/24-cl-joint-rule-15c2-11-extension.pdf).

Clarifying an equity-only scope would reduce the prospect of sudden quotation interruptions in debt markets. Dealer workflows for publishing or submitting quotes could continue without building equity-style disclosure review processes for bonds and asset-backed instruments.

If finalized alongside a legislative carve-out, the framework would better reflect differences between OTC equities and debt market structure. Any remaining implementation details would still require careful compliance planning by broker-dealers and buy-side firms.

Stakeholder views and practical implications

SIFMA, ICI, and CREFC: limit 15c2-11 to equities

Industry groups have pressed for an equity-only scope and a legislative fix. According to news/press-releases/sifma-welcomes-bill-to-prevent-misapplication-of-sec-rule-15c2-11-to-fixed-income-markets” target=”_blank” rel=”nofollow noopener”>SIFMA, the Protecting Private Job Creators Act would prevent the misapplication of an equity-specific rule to fixed-income markets (sifma.org/news/press-releases/sifma-welcomes-bill-to-prevent-misapplication-of-sec-rule-15c2-11-to-fixed-income-markets).

CRE Finance Council emphasizes liquidity risks if debt were swept in. “The misapplication of 15c2-11 has been a looming threat to liquidity,” said Lisa Pendergast, President & CEO at CREFC (crefc.org/cre/cre/content/News/Items/advocacy-items/HouseBillWouldSolve15C211IssueforFixed_Income.aspx).

Compliance operations and retail access if fixed-income relief lapses

If relief lapses and dealers curtail quotations to manage compliance risk, retail access could narrow as fewer securities are displayed or readily tradable. Operationally, firms would face new review workflows unsuited to bond market conventions.

An equity-only clarification or statutory carve-out would avoid forcing dealer quotation checks designed for OTC stocks onto diverse fixed-income instruments. That outcome would support continuity in liquidity management and portfolio operations.

FAQ about SEC Rule 15c2-11

What is H.R. 3959 (the Protecting Private Job Creators Act) and how would it change Rule 15c2-11?

A June 2025 House bill that would codify a fixed-income carve-out, stating Rule 15c2-11 does not apply to quotations of bonds, notes, and asset-backed securities.

How would applying 15c2-11 to fixed income affect liquidity, pricing transparency, and retail investor access?

Industry analyses warn potential quotation limits could thin liquidity, impair price discovery, and constrain retail access, without clear evidence of comparable OTC equity fraud risks.